Sage Therapeutics (SAGE) PT Raised to $123 at Leerink Partners

Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Buy

Chardan Capital Markets upgraded Sage Therapeutics (NASDAQ: SAGE) from Neutral to Buy with a price target of $140.00 following phase III Hummingbird data for brexanolone in PPD.

Analyst Gbola Amusa see a read-across from brexanolone in PPD to other vast-market indications, like MDD, Sage... More

Sage Therapeutics (SAGE) PT Raised to $140 at Canaccord Genuity

Canaccord Genuity raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $140.00 (from $81.00) while maintaining a Buy rating.

Analyst John Newman tells clients to expect FDA approval of Brexanolone which was positive in both Phase 3 PPD trials. The analyst comments "We expect... More

Sage Therapeutics (SAGE) PT Raised to $135 at Cowen

Cowen raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $135.00 (from $90.00) while maintaining a Outperform rating following positive top-line data from the Ph3 HUMMINGBIRD trials of brexanolone in moderate and severe PPD.

Analyst Ritu Baral is optimistic that... More

Sage Therapeutics (SAGE) PT Raised to $105 at Stifel

Stifel raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $105.00 (from $91.00) while maintaining a Buy rating after the company reported positive top-line data from P3 Hummingbird trials with brexanolone (i.v. formulation) in postpartum depression (PPD).

Analyst Adam Walsh this... More

Sage Therapeutics (SAGE) PT Raised to $100 at Needham & Company

Needham & Company raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $100.00 (from $86.00) while maintaining a Buy rating after both IV brexanolone Phase 3 trials in moderate and severe postpartum depression (PPD) hit on the primary efficacy endpoint.

Danielle Brill said it... More

Sage Therapeutics (SAGE) PT Raised to $145 at RBC Capital

RBC Capital raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $145.00 (from $120.00) while maintaining a Outperform rating.

Sage Therapeutics (SAGE) Hits 'Very Significant Milestone' - BMO

BMO Capital analyst Gary Nachman reiterated an Outperform rating and $80 price target on Sage Therapeutics (NASDAQ: SAGE) hit its most important milestone as a company to date with very positive data for Brexanolone in two Phase 3 studies in post-partum depression.

Nachman said... More

SAGE Therapeutics (SAGE): Primary Endpoints in Both Phase III PPD Trials Met - Suntrust

SunTrust Robinson Humphrey analyst, Edward Nash, reiterated his Buy rating on shares of Sage Therapeutics (NASDAQ: SAGE) after the company announced that it has hit the primary endpoint on
both Phase III Hummingbird trials with I.V. administered brexanolone for the treatment of moderate and... More

SAGE Therapeutics (SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary Endpoint

SAGE Therapeutics (NASDAQ: SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary Endpoint

LINK

SAGE Therapeutics (SAGE) Says Brexanolone Achieved Primary Endpoints in Both Phase 3 Trials in Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced positive top-line results from two Phase 3 clinical trials with its proprietary i.v. formulation of brexanolone (USAN; formerly SAGE-547); Study 202B in severe postpartum depression (PPD) and Study 202C in moderate PPD. Brexanolone achieved the primary endpoint in both trials, a mean reduction from baseline in the Hamilton Rating Scale for Depression (HAM-D) total score compared to placebo at 60 hours (Study 202B: p=0.0242 for 90 µg/kg/h dose and p=0.0011 for 60... More